Literature DB >> 26319430

[Treatment of head and neck squamous cell carcinoma recurrences and distant metastases: Highlights of the ASCO Meeting 2015].

L Bußmann1, C-J Busch, R Knecht.   

Abstract

This year also saw a great number of phase II and III studies presented at the ASCO Annual Meeting, in which new drugs (monoclonal antibodies, small molecules) were investigated as an alternative to or in combination with established mono- and polychemotherapy in patients with recurrences or distance metastases from head and neck squamous cell carcinoma (R/M-HNSCC). The studies now presented here describe the different concepts being applied to drug-based treatment of R/M-HNSCC and illustrate the variety of therapeutic approaches to treatment of recurrences and metastases.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26319430     DOI： 10.1007/s00106-015-0055-0

Source DB:  PubMed          Journal:  HNO        ISSN： 0017-6192            Impact factor:   1.284


  10 in total

1.  Human papillomavirus and survival of patients with oropharyngeal cancer.

Authors:  K Kian Ang; Jonathan Harris; Richard Wheeler; Randal Weber; David I Rosenthal; Phuc Felix Nguyen-Tân; William H Westra; Christine H Chung; Richard C Jordan; Charles Lu; Harold Kim; Rita Axelrod; C Craig Silverman; Kevin P Redmond; Maura L Gillison
Journal:  N Engl J Med       Date:  2010-06-07       Impact factor: 91.245

2.  Prognostic significance of VEGF immunohistochemical expression and tumor angiogenesis in head and neck squamous cell carcinoma.

Authors:  Panayiotis A Kyzas; Dimitrios Stefanou; Anna Batistatou; Niki J Agnantis
Journal:  J Cancer Res Clin Oncol       Date:  2005-10-20       Impact factor: 4.553

3.  Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer.

Authors:  Athanassios Argiris; Michalis V Karamouzis; William E Gooding; Barton F Branstetter; Shilong Zhong; Luis E Raez; Panayiotis Savvides; Marjorie Romkes
Journal:  J Clin Oncol       Date:  2011-02-22       Impact factor: 44.544

4.  Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.

Authors:  Jean-Pascal H Machiels; Robert I Haddad; Jérôme Fayette; Lisa F Licitra; Makoto Tahara; Jan B Vermorken; Paul M Clement; Thomas Gauler; Didier Cupissol; Juan José Grau; Joël Guigay; Francesco Caponigro; Gilberto de Castro; Luciano de Souza Viana; Ulrich Keilholz; Joseph M Del Campo; Xiuyu Julie Cong; Eva Ehrnrooth; Ezra E W Cohen
Journal:  Lancet Oncol       Date:  2015-04-16       Impact factor: 41.316

5.  HPV positive squamous cell carcinoma of the oropharynx. Are we observing an unusual pattern of metastases?

Authors:  Susan Müller; Fadlo R Khuri; Scott A Kono; Jonathan J Beitler; Dong M Shin; Nabil F Saba
Journal:  Head Neck Pathol       Date:  2012-04-15

6.  Platinum-based chemotherapy plus cetuximab in head and neck cancer.

Authors:  Jan B Vermorken; Ricard Mesia; Fernando Rivera; Eva Remenar; Andrzej Kawecki; Sylvie Rottey; Jozsef Erfan; Dmytro Zabolotnyy; Heinz-Roland Kienzer; Didier Cupissol; Frederic Peyrade; Marco Benasso; Ihor Vynnychenko; Dominique De Raucourt; Carsten Bokemeyer; Armin Schueler; Nadia Amellal; Ricardo Hitt
Journal:  N Engl J Med       Date:  2008-09-11       Impact factor: 91.245

7.  Angiogenic growth factors in tissue homogenates of HNSCC: expression pattern, prognostic relevance, and interrelationships.

Authors:  Michael Montag; Gerhard Dyckhoff; Jennifer Lohr; Burkhard M Helmke; Eva Herrmann; Peter K Plinkert; Christel Herold-Mende
Journal:  Cancer Sci       Date:  2009-03-31       Impact factor: 6.716

8.  Strong immunohistochemical expression of vascular endothelial growth factor predicts overall survival in head and neck squamous cell carcinoma.

Authors:  Gary M Tse; Anthony W H Chan; Kwok-Hung Yu; Ann D King; Ka-Tak Wong; George G Chen; Raymond K Y Tsang; Amy B W Chan
Journal:  Ann Surg Oncol       Date:  2007-10-11       Impact factor: 5.344

9.  Metastasis occurring eleven years after diagnosis of human papilloma virus-related oropharyngeal squamous cell carcinoma.

Authors:  Jessica Ley; Tanya Wildes; Samir El-Mofty; Douglas Adkins
Journal:  Ecancermedicalscience       Date:  2014-11-13

10.  Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy.

Authors:  Jean-Pascal H Machiels; Lisa F Licitra; Robert I Haddad; Makoto Tahara; Ezra Ew Cohen
Journal:  BMC Cancer       Date:  2014-06-28       Impact factor: 4.430
  10 in total
  1 in total

Review 1.  [Preclinical models in head and neck tumors : Evaluation of cellular and molecular resistance mechanisms in the tumor microenvironment].

Authors:  A Affolter; J Hess
Journal:  HNO       Date:  2016-12       Impact factor: 1.284
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.